Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Margolis, DA; Gonzalez-Garcia, J; Stellbrink, HJ; Eron, JJ; Yazdanpanah, Y; Podzamczer, D; Lutz, T; Angel, JB; Richmond, GJ; Clotet, B; Gutierrez, F; Sloan, L; St Clair, M; Murray, M; Ford, SL; Mrus, J; Patel, P; Crauwels, H; Griffith, SK; Sutton, KC

Margolis, DA (reprint author), ViiV Healthcare, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.

LANCET, 2017; 390 (10101): 1499

Abstract

Background Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated lo......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索